AddedRisk Factors
We rely extensively on information technology systems to conduct our business and collect, store, process and transmit confidential and sensitive information, including personal information of (or relating to) customers, patients and our employees and contractors. These systems support, among other things, manufacturing and distribution, supply chain management, order processing, financial reporting, patients, regulatory and legal compliance and other critical business functions. Our information technology systems, operational technology environments, and those of our third-party service providers, vendors, contract manufacturers, strategic partners and other contractors or consultants are vulnerable to evolving cybersecurity threats. These threats include, but
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedRisk Factors
are not limited to, damage or interruption from computer viruses and malware (e.g. ransomware), misconfigurations, “bugs” or other vulnerabilities, malicious code, terrorism, telecommunication and electrical failures, hacking, cyberattacks, phishing and other social engineering attacks, denial of service attacks, insider threats, human error, fraud, unauthorized access, and attacks by sophisticated nation-state and nation-state-supported actors. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedRisk Factors
utilized and our federal R&D credit carryover was $10.1 million. Future changes in our stock ownership, some of which might be beyond our control, could result in an ownership change under Section 382 of the Code. For these reasons, in the event we experience a change of ownership within the definition of Section 382 of the Code, we may not be able to utilize a material portion of the remaining R&D credit carryforwards, even if we sustain profitability.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedRisk Factors
Fluctuations in our tax obligations and effective tax rate and realization of our net deferred tax assets may result in volatility of our operating results and materially impact our financial condition or financial results.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RemovedRisk Factors
Additionally, securities class action litigations are often brought against companies following periods of volatility in the overall market and in the market price of a company’s securities. On December 22, 2023, we and certain of our executive officers were named in a putative class action lawsuit. The plaintiff filed an amended complaint on April 19, 2024, which alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5, which alleged violations relate to certain prior disclosures of Inspire about the effectiveness of a program intended to help certain customers establish independence in seeking prior authorization from payors for our Inspire therapy. The plaintiff seeks to represent a class of shareholders who purchased or otherwise acquired Inspire common stock between May 3, 2023 and November 7, 2023. The plaintiff seeks damages and other relief, including attorneys' fees and costs. The defendants are vigorously defending this lawsuit. On June 28, 2024, the defendants moved to dismiss the amended complaint in its entirety. The motion was argued in November 2024.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
we may lose sales, experience manufacturing or other delays, incur increased costs or otherwise experience impairment to our customer relationships. We cannot guarantee that we will be able to establish alternative relationships on similar terms, without delay or at all.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
We rely extensively on information technology systems to conduct our business and collect, store and transmit confidential information, including personal information of customers and our employees and contractors. These systems affect, among other things, ordering and managing materials from suppliers, shipping products to customers, processing transactions, summarizing and reporting results of operations, patient marketing, complying with regulatory, legal or tax requirements, data security and other processes necessary to manage our business. Our information technology systems and those of our third-party service providers, vendors, strategic partners and other contractors or consultants are vulnerable to damage or interruption from computer viruses and malware (e.g. ransomware), natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, malicious code, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
As we grow our international presence and global operations, we will have increasing obligations to comply with trade and economic sanctions and other restrictions imposed by the U.S., the EU, and other governments and organizations. During the year ended December 31, 2024, approximately 4.0% of our total sales were made in EU member states and certain Asia Pacific regions. The U.S. Departments of Justice, Commerce, State and Treasury
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
In the EU, both (i) devices lawfully placed on the market pursuant to the EU Medical Devices Directive prior to May 26, 2021 and (ii) legacy devices lawfully placed on the market after May 26, 2021 in accordance with the transitional provisions of the EU Medical Devices Regulation may generally continue to be made available on the market or put into service, provided that the requirements of the transitional provisions are fulfilled. In particular,
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
authority or certified by a notified body, may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
devices, we may face additional regulatory enforcement action, including FDA or foreign regulatory authority warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
Similarly, the EU landscape concerning medical devices recently evolved, and continues to undergo legislative changes. On May 25, 2017, the EU Medical Devices Regulation entered into force, which repeals and replaces
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
are subject to or affected by new and/or existing privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
Some of our intellectual property rights depend on a licensing agreement with a third party, and our patent coverage includes protection provided by licensed patents. Many of these licensed patents are over ten years old and the standard life of a patent is 20 years from its initial filing date. If in the future we no longer have rights to one or more of these licensed patents, our patent coverage may be compromised, which in turn could affect our ability to protect our Inspire system or defend against competitors.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
Moreover, we may become party to future adversarial proceedings regarding our patent portfolio or the patents of third parties. Such proceedings could include supplemental examination or contested post-grant proceedings such as review, reexamination, inter partes review, interference or derivation proceedings before the USPTO and
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RewordedRisk Factors
We are subject to the FDA’s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA and foreign regulatory authorities when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. authorities.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
We are subject to In the FDA’s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA and foreign regulatory authorities when we receive or become aware of U.S., information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. injury must be reported to the FDA.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
Specifically, this final rule, The WMSR, which replaced the FDA expects to go into effect on February 2, 2026, establishes FDA's former Quality System Regulation, sets forth the “Quality Management System Regulation,” or QMSR, which FDA's requirements for medical devices, and among other things, incorporates by reference certain elements of the quality management system requirements of ISO 13485:2016.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, if we experience a significant increase in demand, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or suppliers or our third-party manufacturers may not be able to allocate sufficient capacity in order to meet our increased requirements, which could have an adverse effect on our ability to meet customer demand for our Inspire system and our results of operations.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our estimates and assumptions that support the view that our existing cash, cash equivalents, short-term investments and revenue will be sufficient to meet our capital requirements and fund our operations for at least 12 months. months may prove to be incorrect, and we could spend our available financial resources much faster than we currently expect.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our locations, and those of our customers and suppliers, can be disrupted by droughts, extreme temperatures, fires, flooding and other climate change-related risks, as well as earthquakes, actions by utility providers, and other catastrophic events such as an actual or threatened public health emergency.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
Many aspects of these proposals are unclear or undeveloped, and we We are unable to predict which, if any, U.S. tax reform proposals will be enacted into law, and what effects any enacted legislation might have on our tax liabilities.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we believe that there could be a benefit to our business as a result of GLP-1s reducing the BMI of our prospective patients and increasing the number of eligible patients for our Inspire therapy, there can be no assurance of such benefit.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
The availability of the PTAB as a lower-cost, faster and potentially more potent tribunal for challenging patents could increase the likelihood that our own patents will be challenged, thereby increasing the uncertainties and costs of maintaining and enforcing them.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
Such recalls and withdrawals may also be used by our competitors to harm our reputation for safety or be perceived by patients as a safety risk when considering the use of our products, either of which could have a material adverse effect on our business, financial condition and results of operations.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, the use of our Inspire system for indications other than those approved by the FDA, approved by any foreign regulatory authority or certified by a notified body, may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In recent years, the stock markets generally have experienced extreme significant price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The FDA’s and foreign regulatory bodies' authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury adverse health consequences or death.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If any of the analysts who cover us provide inaccurate or unfavorable research or issue an adverse opinion regarding our stock price, our stock price could decline.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
Third-party payors require physicians and hospitals to identify the service for which they are seeking reimbursement by using Current Procedural Terminology (“CPT") codes, which are created and maintained by the American Medical Association. Our various generations of Inspire therapy have been billed under different codes and reimbursement approaches throughout our history. For example, the procedures performed to implant our Inspire IV device are described for billing purposes using Category I CPT code 64582. And for 2025, the procedures performed to implant our Inspire V device were described for billing purposes using Category I CPT code 64568. There are also other relevant CPT codes for revisions, explants and DISE.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
In November 2025, the final 2026 Medicare reimbursement payments were announced. There has been, and still is currently, confusion on the appropriate reimbursement and coding for our products from CMS and Medicare Administrative Contractors ("MACs"), as well as other payors and stakeholders in the overall reimbursement and coding process. Most recently, we received clarification regarding the coding that should be used for the Inspire V procedure. Currently, healthcare centers and physicians should bill the most recent healthcare policies, be it a Medicare Administrative Contractor (MACs) or a commercial payor, and based on this clarification, we believe the
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
code will transition to CPT code 64582 for the Inspire V procedure, including the use of a -52 modifier. To date, our top commercial payers by volume have all adopted the guidance of 64568 for coding and reimbursement of Inspire V. Confusion will remain until there is definitive and public guidance from various stakeholders and we have sufficient claims data that has been submitted and processed across payers. The resulting coding and reimbursement decisions may impact our business, financial condition and results of operations, in particular our future revenues. We continue to work with the relevant stakeholders to get specific and accurate direction for Inspire V coding, including the -52 modifier that we would expect to reduce the professional fee for Inspire V procedures under CPT code 64582 by approximately 10% to 50% of the base rate. In any case, we believe that a significant decrease in the professional fee resulting from use of the –52 modifier will likely influence physicians’ willingness to perform the Inspire V procedure and may limit the number of cases they choose to undertake. Beyond our short-term initiatives intended to minimize the actual reduction applied to the professional fee, as well as to drive consistency across the country, we are seeking a long-term solution, including the creation of a separate CPT code. There can be no guarantee as to the timing or outcome of the CPT code to be applied.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
We rely on third-party suppliers to manufacture our Inspire system and its components. Many of these suppliers are currently single source suppliers. Currently, all of our manufacturing is done in the U.S. and most components for our Inspire system are sourced in the U.S. We have experienced supply disruptions in the past.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
Since 2023, glucagon-like peptide 1 ("GLP-1s"), a class of drug indicated for diabetes and obesity, has continued to gain popularity as a weight-loss drug. In late 2024, tirzepatide (marketed as Zepbound), a GLP-1 injection which was FDA approved for weight loss in 2023, was also FDA approved for treatment of OSA in patients with obesity and moderate to severe OSA. If GLP-1s are used to treat OSA in an indication for which Inspire therapy is approved, demand for our Inspire system for patients with that indication could be reduced. OSA is a multifactorial disease with many independent factors including age, gender, weight, and neck circumference. Inspire is designed to address antero-posterior airway collapse, also known as tongue base collapse. In contrast, patients with a higher BMI are subject to a larger neck circumference and present predominantly with lateral-wall collapse.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
We recorded a total income tax benefit of $79.7 million for the year ended December 31, 2025 and $4.9 million of expense for the year ended December 31, 2024. The provision for income taxes for fiscal 2025 includes a deferred tax benefit of $88.8 million related to the release of the valuation allowance against our net deferred tax assets, partially offset by current income tax expense of $9.1 million, which reflects federal and state income tax liabilities that are not fully offset by NOLs and credits due to limitations on net operating loss carryforwards and credits under the Internal Revenue Code of 1986, as amended. We expect that we will record income tax expense in 2026 and beyond as we expect to continue to generate additional taxable income for the foreseeable future.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
The primary objective of our investment activities is to preserve our capital for the purpose of funding operations while at the same time maximizing the income we receive from our investments without significantly increasing
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
Prior to December 31, 2025, we maintained a full valuation allowance against all of our net deferred tax assets, and as a result we have historically not recorded an income tax benefit in the accompanying consolidated financial statements. This valuation allowance reflected our assessment of whether it is more likely than not that we would generate sufficient taxable income in the future to be able to utilize our deferred tax assets. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies. We consider all positive and negative evidence to estimate if sufficient future taxable income will be generated to realize our deferred tax assets, and we considered cumulative losses in recent years to be a significant type of negative evidence. As of December 31, 2025, we determined that it is more-likely-than-not that a majority of our federal and state deferred tax assets will be realized. As a result, we recorded a release of the valuation allowance associated with these deferred tax assets, which was due in part to achieving three years of cumulative taxable income and projected taxable income that is more than sufficient to realize our federal and state deferred tax assets, and we recorded a deferred income tax benefit in the amount of $88.8 million for the year ended December 31, 2025 (see Note 7 to our Consolidated Financial Statements included elsewhere in this Form 10-K). We utilize financial projections to support our net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on our ability to realize our net deferred tax assets. Changes in our valuation allowance will result in a change to tax expense.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RemovedMD&A
The procedures performed to implant, revise, or explant our Inspire IV device are described for billing purposes in the U.S. with Category I Current Procedural Terminology codes (64582, 64583, and 64584, respectively). A Category I code (42975) is also used for Drug-Induced Sleep Endoscopy ("DISE") to evaluate sleep disordered breathing, which may be a necessary procedure to determine which patients are appropriate for Inspire therapy. In November 2024, the final 2025 Medicare reimbursement payments were announced. The Medicare national average 2025 payment to implant our Inspire IV device in a hospital outpatient site of service is $30,474, an increase of 3% from the 2024 rate. The 2025 Medicare national average ASC reimbursement is $25,832, an increase of 4% from the 2024 rate. The 2025 Medicare national average physician reimbursement is $816 for implantation of a hypoglossal nerve stimulator, a 1% decrease over the 2024 payment. The reimbursement for the DISE procedure in the hospital setting is $1,724, a 7% increase over the prior year amount. In the ASC setting, the reimbursement for the DISE procedure is $792, a 714% increase from the 2024 amount. The 2025 Medicare national average physician reimbursement for the DISE procedure is $94, a 2% decrease over the prior year amount.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
We rely on third-party suppliers to manufacture our Inspire system and its components. Many of these suppliers are currently single source suppliers. We have experienced supply disruptions that began during the COVID-19 pandemic, but to date we have managed to avoid major delays in implant procedures due to those issues. During the third quarter of 2023, we experienced an inventory supply issue related to our polyurethane-based stimulation leads, one component of the Inspire system used only in the European market at that time. In 2022, the FDA approved our silicone-based stimulation and sensing leads in the U.S., which replaced the polyurethane versions of the leads, and we stopped manufacturing polyurethane leads. We applied for EU MDR certification in December 2021, which we received in July 2024, following industry-wide delays in the process. In the interim, we had received a derogation pursuant to Article 59 of the EU MDR from the Dutch, German, Swiss, Belgian, and Austrian competent authorities, and the British equivalent, i.e. exceptional use authorization, from the United Kingdom national competent authority, allowing us to continue to place the silicone-based leads on the market in those countries until various dates in 2024 or until we received certification under the EU MDR, whichever occurred first. Now that we have obtained certification under the EU MDR, silicone leads may be marketed throughout the EU. During the fourth quarter of 2023 and extending into early 2024, the delay in certification and the shortage of polyurethane-based stimulation leads caused delays to implant procedures which adversely affected our business in Europe, including a reduction in our European revenue, and thereby our consolidated revenue. We estimate the impact during the fourth quarter of 2023 was approximately $4.0 million in lost revenue opportunity, most of which we believe was recovered during the first half of 2024.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
Our products are shipped directly to our U.S. customers and to our Singapore and Hong Kong distributors on a purchase order basis, primarily by a third-party vendor with a facility in Tennessee, although we do ship some products from our facility in Minnesota. Warehousing and shipping operations for our European customers are handled by a third-party vendor with a facility located in the Netherlands, and warehousing and shipping operations for our Japanese customers are handled by a third-party with a facility in Japan. Customers do not have the right to return a non-defective product, nor do we place product on consignment. Our sales representatives do not maintain trunk stock.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
2023, we received approval from the FDA on an expanded indication which includes an increase on the upper limit of the Apnea Hypopnea Index to 100 events per hour from 65 and raises the Body Mass Index ("BMI") warning in the labeling to 40 from 32, and we also received FDA approval of our new physician programmer, called the SleepSync™ programmer, which we launched in the U.S. in late 2024. In March 2023, we received FDA approval to offer Inspire therapy to certain pediatric patients with Down syndrome.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
Our direct-to-consumer marketing program's goals are therapy awareness, connecting patients with providers, and supporting the patient through their path to Inspire from start to finish. Our investments in advertising are designed to increase patient awareness and encourage them to visit our website. On our website, patients can explore educational materials and videos about sleep apnea, learn about the benefits of Inspire therapy, find physician and clinical site contact information, and stay informed about community awareness events. We also use the Inspire Sleep app as a valuable tool for patient education. Moving forward, we plan to refine and optimize our outreach strategies, with an emphasis on expanding digital advertising efforts to reach more qualified patients. We generally expect to maintain our level of direct-to-consumer expenditures.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
We have a call center which we refer to as the Inspire Advisor Care Program. The primary purpose of this program is to assist patients with making a connection with a qualified healthcare provider based on their specific needs. In 2022, we initiated a digital scheduling program to facilitate and streamline patient access to care. We intend to continue to enhance this scheduling capability during 2025.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
We also continue to make significant investments to build our sales and marketing organization by increasing the number of U.S., European, and Japanese sales representatives and continuing our direct-to-consumer marketing efforts in existing and new markets. During 2024, we activated 285 U.S. centers bringing the total to 1,435 U.S. medical centers implanting Inspire therapy as of December 31, 2024. Additionally, we created 48 new U.S. sales territories during 2024, bringing the total to 335 U.S. territories as of December 31, 2024.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
Our inventory on-hand has been constrained by the supply chain challenges and component shortages, although to a lesser degree in 2024 than in prior periods.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
recovery of most of the estimated $4.0 million of revenue opportunity from the fourth quarter of 2023. Other factors contributing to revenue growth were increased market penetration in existing centers, the expansion of our European sales representatives into new territories and centers, the start of reimbursed procedures in France, increased sales in the Asia Pacific region, and, we believe, increased physician and patient awareness of our Inspire system.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
We recorded a provision for income taxes of $4.9 million and $1.2 million for the years ended December 31, 2024 and 2023, respectively. This change was primarily due to an increase in state and local taxes.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
In August 2024, our Board of Directors authorized the repurchase of up to $150.0 million in our common stock through August 5, 2026 (the "Repurchase Program"). In November 2024, we entered into an accelerated share repurchase agreement (“ASR”) with a large financial institution as part of the Repurchase Program, whereupon we paid the counterparties to the ASR $75.0 million for the repurchase of shares of our common stock. In November 2024, we received an initial delivery of 305,157 shares of common stock representing a portion of the prepayment, which shares had an average price paid per share of $196.62. Upon final settlement of this ASR in January 2025, we received an incremental delivery of 103,886 shares of our common stock. Under this ASR, we repurchased a total of 409,043 shares at an average price paid per share of $190.29.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2024, 2025, we generated revenue of $912.0 million with a gross margin of 85.4% and net income of $145.4 million, compared to revenue of $802.8 million with a gross margin of 84.7% and net income of $53.5 million, compared to million for the year ended December 31, 2024, and revenue of $624.8 million with a gross margin of 84.5% and a net loss of $21.2 million for the year ended December 31, 2023, and revenue of $407.9 million with a gross margin of 83.8% and a net loss of $44.9 million for the year ended December 31, 2022. 2023.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
The remainder of the non-cash charges included accretion the recognition of investment discount due to higher investment balances, a deferred tax benefit, depreciation and amortization expense which increased with additional purchases of property and equipment, an impairment of a strategic investment, accretion of investment discount on our available-for-sale investments, a change in the benefit provision for estimated credit losses related primarily to accounts receivable with two healthcare systems, losses, and other non-cash expenses. other, net.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
The non-cash charges consisted primarily of stock-based compensation, which increased mainly as a result of the accelerated recognition of stock-based compensation expense for employees who are retirement eligible in accordance with implementation of changes to the treatment of equity awards under the Inspire Medical Systems, Inc. 2018 Incentive Award Plan upon the holder's death, disability, or retirement, and granting more equity awards to a greater number of employees as compared to the same prior year prior-year period.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
Overall revenue Revenue growth in the U.S. was primarily due to increased market penetration in existing centers, expansion into new territories and centers, penetration, and, we believe, increased physician and patient awareness of our Inspire system, partially offset by ENT surgeon capacity constraints. constraints and some patients and physicians delaying Inspire therapy until Inspire V is available at their location or while they trial GLP-1 medications.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
Overall revenue growth was primarily due to increased market penetration in existing centers, expansion into new territories and centers, penetration, and, we believe, increased physician and patient awareness of our Inspire system, partially offset by ENT surgeon capacity constraints. constraints and some U.S. patients and physicians delaying Inspire therapy until Inspire V is available at their location or while they trial GLP-1 medications.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
Other income, net increased decreased by $2.0 $7.6 million, or 9.8%, 34.1%, to $14.7 million of income for the year ended December 31, 2025 compared to $22.4 million of income for the year ended December 31, 2024 compared to $20.4 million of income for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
Operating assets include inventories, which increased as supply chain constraints continued we continue to ease and build inventory on hand increased levels to support higher sales and the launch of our next generation Inspire system, V, and accounts receivable, which increased primarily due to the higher sales volume we typically experience late in the fourth quarter. which occurred during September 2025.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
See section titled “Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities” in Part II, Item 5 of this report for a discussion of our share repurchase program and related stock repurchases during the quarter ended December 31, 2024 and 2025 as well as Note 6 of our Notes 5 to our Consolidated Financial Statements for further details regarding our Repurchase Program. included elsewhere in this Form 10-K.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
This change was primarily due to an increase decrease of $2.7 $5.7 million in interest and dividend income due to higher lower cash, cash equivalents, and investment balances, an impairment charge of $4.0 million on one of our strategic investments, and an increase of $0.1 million in interest expense, partially offset by an increase in net losses of $0.7 $2.2 million in foreign currency translation and remeasurement gains due to exchange rates.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
Based on our ongoing ADHERE patient registry, the average BMI of patients treated with Inspire therapy is 29 and the American Academy of Sleep Medicine guidelines recommend weight loss prior to surgery for patients with BMI over 35 and nonsurgical solutions for patients with BMI over 40. 29.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in financing activities was $52.4 $183.4 million for 2024 2025 and consisted primarily of a $75.0 share repurchases of $175.0 million under our share repurchase authorizations and the payment for our ASR agreement and $5.2 of $23.0 million of taxes paid on net share settlement of equity awards, partially offset by proceeds from the exercise of stock options of $22.2 $9.6 million and proceeds from the issuance of common stock from our Employee Stock Purchase Plan ("ESPP") of $5.6 $5.0 million.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of goods sold increased $26.4 $10.2 million, or 27.3%, 8.3%, to $133.2 million for the year ended December 31, 2025 compared to $123.0 million for the year ended December 31, 2024 compared to $96.6 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new